Delamanid: A new armor in combating drug‑resistant tuberculosis
Alphienes Stanley Xavier1★, Mageshwaran Lakshmanan1★ Corresponding author
- 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
CORRESPONDENCE
Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Received: 20-01-2014; Revised: 08-03-2014; Accepted: 03-04-2014.
Volume 5, Issue 3 · pp. 222–224 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.136121
ABSTRACT
Intense search has been made in the discovery of newer anti‑TB drugs to tackle the issues such as drug resistance, HIV co‑infection and risk of drug‑drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Xavier, A. S., & Lakshmanan, M. (2014). Delamanid: A new armor in combating drug‑resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics, 5(3), 222–224. https://doi.org/10.4103/0976-500X.136121